Article
Medicine, Research & Experimental
Ester Simeone, Giosue Scognamiglio, Mariaelena Capone, Diana Giannarelli, Antonio M. Grimaldi, Domenico Mallardo, Gabriele Madonna, Marcello Curvietto, Assunta Esposito, Fabio Sandomenico, Francesco Sabbatino, Nicholas L. Bayless, Sarah Warren, SuFey Ong, Gerardo Botti, Keith T. Flaherty, Soldano Ferrone, Paolo A. Ascierto
Summary: Studies have shown that the combination of vemurafenib and IFN-alpha may benefit patients with BRAFV600E melanoma, with IFNAR1 expression levels correlating with treatment response and survival. The vemurafenib + PEG-IFN-alpha-2b + cobimetinib combination showed overall safety, but may face challenges in finding a niche in current treatment scenarios for advanced melanoma.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Medicine, General & Internal
Yun-Suk Choi, Seong-Woon Choi, Jin-Wook Yi
Summary: This study identified TERT promoter mutations in PTC and found that they are associated with more aggressive behavior. Patients with TERT promoter mutations were older, had larger tumors, and exhibited other adverse clinical features, resulting in a poorer prognosis compared to those with wild-type TERT gene status.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
Anastasios Maniakas, Ying C. Henderson, Hu Hei, Shaohua Peng, Yunyun Chen, Yujie Jiang, Shuangxi Ji, Maria Cardenas, Yulun Chiu, Diana Bell, Michelle D. Williams, Marie-Claude Hofmann, Steve E. Scherer, David A. Wheeler, Naifa L. Busaidy, Ramona Dadu, Jennifer R. Wang, Maria E. Cabanillas, Mark Zafereo, Faye M. Johnson, Stephen Y. Lai
Summary: This study developed and characterized 6 novel ATC PDX models with 4 matching cell lines, each with distinct genetic profiles. The PDX models showed remarkable resemblance to the original patient surgical specimens and had strong concordance with the original tumor in terms of genetic characteristics. These models can serve as excellent tools for preclinical therapeutic trials.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Review
Oncology
Jiaqian Yuan, Yong Guo
Summary: Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive tumor that is resistant to traditional antitumor therapies. In recent years, targeted therapy has emerged as a promising treatment strategy, offering hope to patients with this malignant disease. This review summarizes the efficacy and adverse effects of various targeted drugs, providing valuable information for future research and clinical decision-making.
Article
Endocrinology & Metabolism
Ines Califano, Anabella Smulever, Fernando Jerkovich, Fabian Pitoia
Summary: ATC is a rare thyroid tumor that mainly affects elderly patients. It is characterized by a rapidly growing cervical mass and often presents with metastases at diagnosis. Treatment with a combination of BRAF and MEK inhibitors has improved overall survival in patients with BRAF-mutated ATC. However, effective therapies are still needed for patients with BRAF wild-type ATC, and more high-quality evidence is needed to guide treatment decisions.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
(2023)
Article
Oncology
Ga Hyun Kim, Hye Jin Heo, Ji Wan Kang, Eun-Kyung Kim, Seung Eun Baek, Keunyoung Kim, In Joo Kim, Sunghwan Suh, Byung-Joo Lee, Yun Hak Kim, Kyoungjune Pak
Summary: This study identified TEK and AXIN2 as potential factors involved in the multifocality of papillary thyroid carcinoma (PTC). In vitro experiments showed that inhibiting TEK and AXIN2 reduced the proliferation and migration of PTC cells. Additionally, serum TEK may serve as a diagnostic marker for multifocal PTC.
CANCER CELL INTERNATIONAL
(2022)
Article
Multidisciplinary Sciences
Valentina D. Yakushina, Vladimir V. Strelnikov, Alexander S. Tanas, Alexander V. Lavrov
Summary: This study identified common and specific long noncoding RNAs in follicular adenoma, classical papillary thyroid carcinoma, follicular variant of papillary thyroid carcinoma, and anaplastic thyroid carcinoma. These findings enhance our understanding of the role of long noncoding RNAs in the development of subtype-specific features in thyroid cancer.
SCIENTIFIC REPORTS
(2021)
Review
Endocrinology & Metabolism
Christian Okafor, Julie Hogan, Margarita Raygada, Barbara J. Thomas, Srivandana Akshintala, John W. Glod, Jaydira Del Rivero
Summary: Medullary thyroid carcinoma is a rare neuroendocrine tumor linked to RET gene mutations. The development of new RET-targeting therapies provides effective options for treatment, but resistance remains a challenge.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Jiangyue Xu, Ke Ding, Lan Mu, Jiangsheng Huang, Fei Ye, Yu Peng, Can Guo, Chutong Ren
Summary: This study found that Hashimoto's thyroiditis (HT) is associated with thyroid carcinoma (TC), where HT is a risk factor for TC and papillary thyroid carcinoma (PTC), but acts as a protective factor against PTC progression.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Riet Hilhorst, Adrienne van den Berg, Piet Boender, Tom van Wezel, Tim Kievits, Rik de Wijn, Rob Ruijtenbeek, Willem E. Corver, Hans Morreau
Summary: STK activity profiling can accurately differentiate benign and malignant thyroid tumors and generate unbiased hypotheses regarding differentially active kinases. This approach can serve as a model for selecting novel kinase inhibitors for the treatment of recurrent thyroid and other cancers.
Article
Oncology
Catherine Leyh, Ursula Ehmer, Daniel Roessler, Alexander B. Philipp, Florian P. Reiter, Petia Jeliazkova, Leonie S. Jochheim, Matthias Jeschke, Janina Hammig, Johannes M. Ludwig, Jens M. Theysohn, Andreas Geier, Christian M. Lange
Summary: This study compared the sequential systemic therapy after first-line therapy with sorafenib or lenvatinib and discontinuation of therapy in patients with liver cancer. The results showed that liver functional status and patient performance status at the beginning of first-line therapy had an impact on median overall survival (mOS), while the choice of the initial tyrosine kinase inhibitor (TKI) did not affect mOS.
Article
Medicine, Research & Experimental
Peng Chen, Xiaoyao Cai, Ganen Mu, Yuansheng Duan, Chao Ji Ng, Zhimou Yang, Cuihong Yang, Xudong Wang
Summary: The study developed a self-assembling peptide nanofiber (SPNs) loaded with dabrafenib (Da) and doxorubicin (Dox) for targeted and synergistic therapy of BRAF V600E+ thyroid cancer.
Article
Oncology
Filip Janku, Divya Sakamuri, Shumei Kato, Helen J. Huang, S. Greg Call, Aung Naing, Veronica R. Holley, Sapna P. Patel, Rodabe N. Amaria, Gerald S. Falchook, Sarina A. Piha-Paul, Ralph G. Zinner, Apostolia M. Tsimberidou, David S. Hong, Funda Meric-Bernstam
Summary: The study found that combining vemurafenib with sorafenib or crizotinib could overcome therapeutic resistance in patients with BRAF mutations, and showed good tolerability and encouraging activity. Optional longitudinal collection of plasma to assess dynamic changes in circulating tumor DNA demonstrated the elimination of BRAF-mutant DNA from plasma during therapy (P = .005).
Article
Biotechnology & Applied Microbiology
Serena De Matteis, Martina Ghetti, Laura Gramantieri, Giorgia Marisi, Andrea Casadei-Gardini
Summary: Hepatitis B and C virus infections contribute to the development of hepatocellular carcinoma through various mechanisms, and different virus-related etiologies may affect treatment response in HCC. Molecular, metabolic, and microenvironmental factors also play a role in influencing the treatment outcomes of HCC.
ONCOTARGETS AND THERAPY
(2021)
Review
Oncology
Tomohiro Enokida, Makoto Tahara
Summary: Anti-VEGFR therapy is crucial in treating thyroid cancer but can lead to dangerous adverse reactions. To minimize risks, physicians need to understand the characteristics of these reactions and take appropriate measures. The development of multitarget tyrosine kinase inhibitors has improved prognosis, but effective management of related adverse events is essential.